Nonsyndromic Hearing Loss and Deafness, DFNA23

Nonsyndromic Hearing Loss and Deafness, DFNA23 is a type of inherited, autosomal dominant, nonsyndromic hearing loss. “Autosomal dominant” means a single altered gene copy—from either parent—can cause the condition. “Nonsyndromic” means the hearing loss occurs without other medical features (no kidney, branchial, or craniofacial anomalies that define certain syndromes). DFNA23 is caused by disease-causing variants (mutations) in the SIX1 gene, a transcription factor crucial for inner-ear development. Families with DFNA23 typically have prelingual (before speech develops), bilateral, symmetric hearing loss that may be high-frequency predominant and sometimes progressive; a conductive component has been reported in some, but not all, patients. Monarch Initiative+2MalaCards+2

DFNA23 is a rare, inherited, nonsyndromic hearing loss. “Nonsyndromic” means the hearing loss happens by itself, without other medical problems. DFNA23 usually runs in families in an autosomal dominant way—if a parent has the condition, there is a 1 in 2 chance their child will have it. Scientists have linked DFNA23 to changes (variants) in a gene called SIX1, which is important for inner ear development and hearing. People with DFNA23 often have prelingual (before speech) or early-life sensorineural hearing loss that is typically bilateral (both ears) and symmetric. PubMed+2GeneCards+2

Researchers first mapped DFNA23 as a new locus (position) on chromosome 14 in a Swiss-German family where many relatives had early-onset, symmetric hearing loss. Later, scientists found that variants in the SIX1 gene at that region can cause DFNA23. Some SIX1 changes can also cause branchio-oto(-renal) spectrum disorders, which include ear pits and kidney issues; however, DFNA23 refers to cases where hearing loss occurs without other clear features. PubMed+2ScienceDirect+2

SIX1 works together with EYA proteins to control gene programs that shape the otic placode and cochlea (the hearing organ). Alterations in SIX1 can disrupt this EYA1–SIX1–DNA complex, leading to abnormal development or maintenance of cochlear hair cells and supporting structures—producing the DFNA23 phenotype without the extra-ear findings seen in some SIX1-related syndromes. Nature

Other names

• Autosomal dominant nonsyndromic hearing loss 23

• DFNA23

• SIX1-related autosomal dominant nonsyndromic hearing loss (descriptive) National Organization for Rare Disorders+1

Types

Although DFNA23 is one genetic entity (SIX1-related), clinicians often describe it by clinical pattern to guide testing and care:

1. By onset: Most reports describe prelingual onset (hearing loss is present before speech develops). PMC

2. By laterality and symmetry: Bilateral and symmetric loss are typical. PMC

3. By configuration: Many families show high-frequency greater than low-frequency loss on the audiogram. MalaCards

4. By progression: Some individuals demonstrate progression over time, others are more stable. MalaCards

5. By mechanism (audiologic): Primarily sensorineural; a conductive component has been observed in some. MalaCards

6. By inheritance: Autosomal dominant with vertical transmission across generations. PMC

7. By genotype–phenotype: Different SIX1 variant types/locations (e.g., affecting the homeodomain or interaction with EYA1) can shift severity and pattern. Nature

Context: DFNA = autosomal dominant deafness loci; DFNB = autosomal recessive; DFNX = X-linked. These naming rules are standard in nonsyndromic hearing-loss genetics. MDPI

Causes

DFNA23 has a single fundamental cause—pathogenic variants in SIX1. Below are 20 ways or mechanisms this can present or be modified in real life. Each item is a short, plain-English paragraph.

1. SIX1 loss-of-function variants. Some variants reduce or abolish SIX1’s activity, so key inner-ear genes are not switched on correctly during development. Nature

2. Dominant-negative SIX1 effects. A faulty SIX1 protein can interfere with the normal protein, worsening the impact even when one healthy copy remains. Nature

3. Disrupted EYA1–SIX1 binding. If a variant weakens SIX1’s partnership with EYA1, the complex cannot bind DNA as needed, leading to cochlear maldevelopment. Nature

4. Altered DNA binding. Variants in the SIX1 homeodomain may reduce precise DNA binding to target genes that guide hair-cell formation. Nature

5. Abnormal hair-cell differentiation. When the gene program falters, inner and outer hair cells may not mature correctly, reducing sound transduction. Nature

6. Disrupted cochlear patterning. The gradients and cell identities along the cochlear spiral can be altered, yielding high-frequency-predominant loss. MalaCards

7. Supporting-cell defects. SIX1 impacts supporting cells that shape the organ of Corti; maldevelopment here can indirectly impair hair-cell function. Nature

8. Stria vascularis effects. Developmental deviations can affect endolymph homeostasis and the endocochlear potential needed for hearing. (Mechanistic inference consistent with SIX1’s developmental role.) Nature

9. Conductive component in some cases. Middle-ear structures may be variably affected, adding a conductive element to an otherwise sensorineural pattern in a subset. MalaCards

10. Variant-specific severity. Different SIX1 changes can produce milder or more severe hearing loss, explaining variability between families. ScienceDirect

11. Modifier genes. Other genes in the same developmental network may amplify or soften the effect of a SIX1 variant, changing the clinical picture. (General principle in nonsyndromic HL genetics.) PMC

12. Allelic heterogeneity. Multiple distinct pathogenic variants within SIX1 can cause DFNA23, each with its own functional impact. Nature

13. Incomplete penetrance. Some carriers may have milder audiograms or later detection, creating the appearance of “skipped” generations. (Recognized in autosomal dominant HL in general.) PMC

14. Age-related progression. Progressive loss in some adults reflects ongoing vulnerability of hair cells that developed with subtle deficits. MalaCards

15. Environmental stressors as modifiers. Loud noise or ototoxic drugs do not cause DFNA23, but may worsen hearing if hair cells are already fragile. (General nonsyndromic HL care principle.) MedlinePlus

16. Epigenetic influences. How tightly DNA is packaged or marked can alter SIX1 target-gene expression, subtly shifting severity. (Mechanistic inference within transcription-factor disorders.) PMC

17. Developmental timing. If SIX1 function is most needed before birth, deficits present as prelingual hearing loss. PMC

18. Pathway network effects. SIX1 sits in a wider otic-development network; disruptions ripple through multiple downstream genes. Nature

19. Cochlear microanatomy vulnerability. High-frequency regions at the cochlear base are often first affected in genetic HL, matching many DFNA23 audiograms. MalaCards

20. Clinical ascertainment bias. Families with more obvious early hearing loss are more likely to be studied and labeled as DFNA23, shaping the classic description. (Epidemiologic context.) PMC

Symptoms

1. Early-life hearing difficulty. Many affected infants/children fail newborn screening or struggle with sound awareness before speech. PMC

2. Bilateral, symmetric loss. Both ears are affected to a similar degree. PMC

3. High-frequency hearing trouble. Voices sound less crisp; consonants like “s,” “f,” and “t” are harder to hear. MalaCards

4. Possible progression. Hearing may decline over years in some individuals. MalaCards

5. Speech and language delay. If not identified and supported early, delayed expressive language can occur.

6. Learning and classroom challenges. Background noise makes listening and participation difficult.

7. Difficulty localizing sound. Because loss is bilateral, pinpointing where a sound comes from can be harder.

8. Hearing in noise is especially hard. Crowded rooms and open classrooms are challenging.

9. Turning up devices. People may increase TV or headphone volume to hear clearly.

10. Frequent “what?” or mishearing. Repeated requests for repetition are common.

11. Listening fatigue. Concentrating to hear can be tiring.

12. Tinnitus (sometimes). Some people report ringing or buzzing, though this is not universal.

13. No vestibular symptoms typical. Dizziness/imbalance are not core DFNA23 features and suggest another issue if present. (Nonsyndromic profile.) MedlinePlus

14. No external anomalies. Unlike branchio-oto-renal (BOR) syndrome, DFNA23 lacks branchial, facial, or kidney anomalies. PNAS

15. Family history. Multiple generations with similar hearing loss pattern strongly suggest a dominant inherited form like DFNA23. PMC

Diagnostic tests

A. Physical Exam (Ear/General) 

1. Otoscopy (ear-canal/tympanic membrane exam). Looks for wax, infection, or eardrum disease. In DFNA23, this is usually normal; a normal exam points to sensorineural loss. (General nonsyndromic HL approach.) MedlinePlus

2. Craniofacial inspection. Screens for outer-ear anomalies; absence supports a nonsyndromic diagnosis like DFNA23. MedlinePlus

3. Neck exam for branchial pits/cysts. Their absence supports DFNA23 over BOR syndrome (also SIX1-related). PNAS

4. General systems review. Looks for syndromic features (renal, ocular, cardiac) that would suggest other diagnoses; usually none in DFNA23. MedlinePlus

5. Family pedigree charting. A three-generation family tree can reveal autosomal dominant transmission typical of DFNA23. PMC

B. Manual/Bedside Tests 

6. Whispered-voice or finger-rub tests. Simple screening that may suggest bilateral loss; formal audiometry is still required.

7. Tuning-fork (Rinne). Air vs bone conduction helps identify conductive vs sensorineural components; DFNA23 is primarily sensorineural. (Some may show mixed patterns.) MalaCards

8. Tuning-fork (Weber). Midline test that lateralizes to the better ear in sensorineural loss; patterns help confirm audiogram findings.

C. Lab/Pathological/Genetic

9. Targeted SIX1 gene sequencing. The key test to confirm DFNA23 is identifying a pathogenic SIX1 variant. Monarch Initiative

10. Comprehensive hearing-loss gene panel (NGS). Panels survey dozens of genes; useful when the family history is unclear or when multiple DFNA genes are possible. PMC

11. Copy-number analysis (CNV). Looks for exonic deletions/duplications if sequencing is negative but suspicion remains. PMC

12. Variant classification with segregation. Classifies the variant (pathogenic/likely pathogenic) and shows it tracks with hearing loss across the pedigree. PMC

13. Re-analysis over time. As knowledge grows, reinterpreting variants can change a “VUS” to “likely pathogenic.” (Standard genetics practice.) Hereditary Hearing Loss

14. Prenatal/preimplantation options (case-by-case). For families with a known variant, counseling can discuss reproductive testing choices. (General hereditary HL counseling.) MedlinePlus

D. Electrodiagnostic/Audiologic 

15. Pure-tone audiometry. Measures thresholds at different frequencies; DFNA23 often shows bilateral, symmetric, high-frequency loss and can track progression. MalaCards

16. Speech audiometry. Assesses speech-recognition thresholds and word scores; consonant clarity is often reduced in high-frequency loss.

17. Tympanometry & acoustic reflexes. Typically normal middle-ear pressure/compliance in pure sensorineural loss; can detect a conductive component if present. MalaCards

18. Otoacoustic emissions (OAE) and/or ABR. OAEs are reduced/absent when hair cells are affected; ABR helps rule out neural pathway disorders and is key for infants. (General pediatric HL diagnostics.) MedlinePlus

E. Imaging –

19. High-resolution temporal-bone CT. Usually normal in nonsyndromic genetic loss, but rules out ossicular/otic capsule malformations if a conductive element is suspected. MedlinePlus

20. MRI of inner ear and auditory nerve. Assesses cochlear nerve integrity and inner-ear fluids; typically normal in DFNA23 but important in pre-implant assessment or atypical findings. MedlinePlus

Non-pharmacological treatments (therapies & others)

(Each item explains what it is, its purpose, and a simple mechanism.)

1. Early family-centered counseling
   Explaining the genetic nature of DFNA23 helps families plan hearing support, school needs, and realistic goals. Counseling also discusses inheritance and testing options for relatives. Purpose: informed decisions; Mechanism: knowledge reduces delay and improves uptake of rehabilitation. NCBI

2. Newborn and early childhood hearing screening + prompt referral
   If a baby fails a hearing screen, early diagnostic testing and early intervention lead to better language, school, and social outcomes. Purpose: catch hearing loss early; Mechanism: early auditory access supports brain speech centers during critical windows. EFHOH+1

3. Hearing aids (digital, appropriately fitted)
   Modern digital hearing aids amplify sounds in the frequencies where loss is present and compress loud sounds to comfort. Purpose: improve audibility and speech clarity; Mechanism: amplification + signal processing tailored to the audiogram. PMC+1

4. Remote microphone / FM or DM systems
   A teacher or speaker wears a small microphone that streams speech directly to the listener’s hearing aids, improving listening in noise and over distance. Purpose: better speech-in-noise understanding; Mechanism: improves signal-to-noise ratio at the ear. PMC

5. Cochlear implant (CI) evaluation and implantation when indicated
   For severe-to-profound loss or limited benefit from hearing aids, a CI can bypass damaged hair cells and directly stimulate the auditory nerve. Purpose: restore access to sound; Mechanism: array electrodes deliver coded electrical signals to the cochlea. (CIs are FDA-approved devices with specific indications.) FDA Access Data+2FDA Access Data+2

6. Bimodal hearing (CI in one ear + hearing aid in the other)
   Combining a CI and a hearing aid can improve sound richness and localization compared to either alone in some users. Purpose: maximize binaural cues; Mechanism: electric-acoustic stimulation uses complementary information. PMC

7. Bilateral cochlear implants (when criteria are met)
   Some children and adults benefit from implants in both ears to improve localization and hearing in noise. Purpose: binaural benefits; Mechanism: synchronized stimulation of both auditory nerves. FDA Access Data

8. Auditory brainstem implant (rare, special cases)
   If the cochlear nerve cannot be used (not typical for DFNA23), an ABI sends sound signals to the brainstem. Purpose: access to sound when CI isn’t possible; Mechanism: direct stimulation of cochlear nucleus. (Specialized indication.) PMC

9. Aural/oral speech-language therapy
   Structured therapy teaches listening strategies, articulation, and spoken language, especially important when hearing loss starts early. Purpose: optimize communication; Mechanism: repeated, guided auditory-verbal practice builds neural pathways. PMC

10. Sign language and bilingual communication
    Using a visual language alongside devices can protect language development and reduce language deprivation, especially in children. Purpose: ensure full language access; Mechanism: visual language provides robust input independent of device performance. The Guardian

11. Captioning (live caption apps, CART, closed captions)
    Captions support understanding in lectures, meetings, and media. Purpose: accessible communication; Mechanism: text supplements or replaces missed auditory information. PMC

12. Alerting and safety tech
    Vibrating or flashing alarms for doorbells, smoke detectors, and phones improve safety and independence. Purpose: ensure alerts are not missed; Mechanism: converts sound into visual or tactile signals. PMC

13. Classroom accommodations (IEP/504 or local equivalents)
    Preferential seating, quiet classrooms, and teacher mic use improve learning. Purpose: reduce listening effort; Mechanism: environmental and instructional supports. PMC

14. Telecoils and Bluetooth streaming
    Direct wireless connection from mics, phones, or loop systems can improve clarity by reducing background noise. Purpose: clearer input; Mechanism: direct audio streaming to hearing devices. PMC

15. Tinnitus education and sound therapy (if present)
    Masking sounds, counseling, and device adjustments can reduce tinnitus distress. Purpose: improve quality of life; Mechanism: reduce salience and stress responses to tinnitus. PMC

16. Vestibular rehabilitation (if balance symptoms occur)
    Targeted exercises retrain balance and reduce dizziness in those with vestibular involvement. Purpose: reduce falls and dizziness; Mechanism: central compensation through graded movement. PMC

17. Noise protection (hearing conservation)
    Use well-fitting earplugs/earmuffs in loud places. Purpose: prevent additional noise-induced damage; Mechanism: reduces harmful sound energy reaching cochlea. PMC

18. Avoiding ototoxic exposures when possible
    Some drugs and chemicals can harm hearing. Clinicians weigh risks and choose safer alternatives if feasible. Purpose: preserve remaining hearing; Mechanism: reduce toxic injury to hair cells/neurons. U.S. Food and Drug Administration

19. Regular audiology follow-up
    Routine checks track hearing, fine-tune devices, and catch changes early. Purpose: keep performance optimal; Mechanism: iterative fitting and counseling. PMC

20. Genetic counseling and cascade testing
    Offering SIX1 testing to at-risk relatives can clarify who needs monitoring and early support. Purpose: proactive care; Mechanism: identify carriers/affected individuals early. NCBI

---

Medicines

There are no FDA-approved drugs that treat or cure DFNA23 or hereditary sensorineural hearing loss. Current expert sources and NIH state that no pharmacologic therapy is approved to prevent or reverse SNHL; gene therapy for hearing loss is under study but not FDA-approved. Your best-proven options today are hearing technology and communication therapies. Frontiers+1

You asked for “20 drug treatments sourced from accessdata.fda.gov for this disease condition” with class, dose, timing, purpose, mechanism, and side effects. For DFNA23, such FDA-approved drugs do not exist. Listing 20 medicines as if they were approved for DFNA23 would be inaccurate and unsafe. Instead, here’s the one related, approved drug in the hearing space—and what it does (note: it does not treat DFNA23):

Sodium thiosulfate (Pedmark®) – FDA-approved only to reduce the risk of cisplatin-induced ototoxicity in pediatric cancer patients; it does not treat genetic deafness. Class: detoxifying agent. Dose/Timing: label-based, body-surface-area dosing given 6 hours after cisplatin. Purpose: protect against chemo-related hearing damage. Mechanism: binds toxic platinum species. Side effects: nausea, vomiting, metabolic changes (see label). Not indicated for DFNA23. FDA Access Data+1

Because no other FDA drug is approved for hereditary SNHL, the rest of this section would be misleading if I fabricated drugs. If you’d like, I can summarize emerging (not-yet-approved) therapies—like OTOF gene therapy trials—in a separate section. Reuters+2Lilly Investor Relations+2

---

Dietary molecular supplements

There is no supplement proven to cure DFNA23. Some nutrients are being studied for general ear health or noise-related risks. Evidence varies; always discuss with a clinician.

1. Omega-3 (DHA/EPA)
   Long-chain omega-3s from fish are linked to lower risk of age-related hearing loss in population studies; they may support inner-ear blood flow and reduce inflammation. Typical study intakes equal 1–2 fish servings/week or fish-oil doses per product label. Function: vascular and anti-inflammatory support; Mechanism: membrane fluidity, vasodilation, anti-inflammatory signaling. PMC+1

2. Magnesium
   Magnesium may help protect against noise-related hearing damage by improving inner-ear blood flow and reducing excitotoxic injury; evidence includes human and animal studies. Doses vary; avoid in severe kidney disease. Function: vasodilator, calcium antagonist; Mechanism: reduces vasoconstriction and oxidative stress. NCBI+1

3. N-Acetylcysteine (NAC)
   As a glutathione precursor, NAC has shown mixed but sometimes positive effects against noise-induced temporary threshold shifts. Not a cure for genetic deafness. Typical research doses vary widely. Function: antioxidant support; Mechanism: replenishes inner-ear glutathione. PubMed+1

4. Folate (vitamin B9)
   Lower folate levels have been associated with worse hearing outcomes in older adults; folate supports vascular and neural health. Function: methylation, vascular support; Mechanism: lowers homocysteine, supporting cochlear microcirculation. EatingWell

5. Vitamin D (adjunct for general health)
   Evidence is indirect; maintaining adequate vitamin D supports bone and immune health, which can influence middle-ear and overall wellness. Function: bone/immune support; Mechanism: genomic regulation. (General health rationale; not DFNA23-specific.) PMC

6. Coenzyme Q10
   As a mitochondrial cofactor and antioxidant, CoQ10 is explored for oxidative stress reduction; evidence for hearing outcomes is limited. Function: antioxidant; Mechanism: supports mitochondrial electron transport. MDPI

7. Zinc
   Zinc supports synaptic and immune function; data for hearing outcomes are limited and mixed. Avoid high chronic doses. Function: cofactor in enzymes; Mechanism: antioxidant enzyme support. PMC

8. Vitamin C
   Acts as an antioxidant; sometimes combined with NAC/Mg in research on noise exposure. Function: scavenges reactive oxygen species; Mechanism: reduces oxidative stress. MDPI

9. Vitamin E
   Another antioxidant used in combination regimens studied for noise-related risk; evidence is mixed. Function: membrane antioxidant; Mechanism: protects lipid membranes from peroxidation. MDPI

10. Calcium (balanced with magnesium)
    Observational work suggests calcium/magnesium balance may relate to hearing health; excessive or deficient calcium can affect cochlear processes. Function: ionic balance; Mechanism: interacts with hair-cell signaling; maintain dietary balance. Frontiers

---

Immunity-booster / regenerative / stem-cell drugs

For transparency: there are no FDA-approved regenerative or stem-cell drugs for hereditary sensorineural hearing loss (including DFNA23). Gene and cell therapies are experimental in clinical trials (for example, OTOF gene therapy). Listing six FDA-approved “regenerative” drugs for DFNA23 would be incorrect. NIDCD+1

---

Surgeries

Cochlear implant surgery
A small electrode array is inserted into the cochlea; an internal receiver is placed under the skin. After healing, an external processor sends coded sound to the electrodes. Why: when hearing aids give little benefit in severe-to-profound loss, CIs can restore speech understanding. (FDA-approved indications; age thresholds have expanded over time.) FDA Access Data+1

Bilateral cochlear implantation
Two implants (same surgery or staged) improve hearing in noise and sound localization compared with one. Why: binaural advantages in eligible patients. FDA Access Data

Cochlear implant for single-sided deafness (selected cases)
Some FDA approvals include unilateral deafness with normal hearing in the other ear. Why: reduce head-shadow effect, improve localization and hearing in noise. FDA Access Data

Bone-anchored hearing system (for special patterns of loss)
An implant couples vibrations to skull bone to stimulate the inner ear; usually for conductive/mixed loss or single-sided deafness, not typical DFNA23. Why: option when air-conduction aids are not suitable. (Device-specific indications vary.) PMC

Auditory brainstem implant (rare)
Implant electrode on the cochlear nucleus of the brainstem when the cochlear nerve cannot be used. Why: last-resort access to sound in specific anatomic conditions. PMC

---

Proven prevention tips

1. Protect your ears from loud noise with proper earplugs/earmuffs. Noise adds damage on top of genetic loss. PMC

2. Avoid or minimize ototoxic medicines/chemicals where alternatives exist; ask your clinician before changes. U.S. Food and Drug Administration

3. Vaccinate as advised, especially for meningitis if you’re a CI candidate/user. PMC

4. Get regular hearing checks to adjust devices as needs change. PMC

5. Use remote mics/FM in noisy places (schools, meetings). PMC

6. Ensure language access for children—spoken, signed, or both—so language develops on time. The Guardian

7. Practice safe listening with headphones (60/60 rule: ≤60% volume for ≤60 minutes at a time). PMC

8. Manage cardiovascular risks (blood pressure, diabetes, smoking) to support the inner ear’s microcirculation. PMC

9. Use captioning and accessibility features early to reduce listening fatigue. PMC

10. Offer genetic counseling/testing to relatives so they can monitor children early. NCBI

---

When to see a doctor

See an audiologist or ENT as soon as you notice reduced hearing, speech delays in a child, new tinnitus, or trouble hearing in noise. Urgent care is needed for sudden hearing loss, new severe dizziness, ear pain, or drainage. Early evaluation speeds access to hearing technology and therapy; urgent treatment matters for sudden losses. PubMed+1

---

What to eat and what to avoid

Eat: a balanced diet with fish 1–2 times per week (omega-3s), fruits/vegetables rich in folate and antioxidants, and foods supplying magnesium (legumes, nuts, seeds). These choices support vascular and general health that also benefits the inner ear. PMC+2American Journal of Clinical Nutrition+2

Avoid/excess: extremely loud venues without protection; smoking; and unnecessary use of ototoxic drugs or chemicals without medical advice. Diets that are very high in salt, sugar, or alcohol can worsen general cardiovascular health; better heart health supports better inner-ear blood flow. (General health guidance; not DFNA23-specific cures.) PMC

---

FAQs

1. Is DFNA23 the same as SIX1-related hearing loss?
   Yes. DFNA23 is the label for nonsyndromic hearing loss caused by changes in SIX1. GeneCards

2. Can DFNA23 appear without other body problems?
   Yes. Many families have only hearing loss; others may show minor ear or kidney findings depending on the variant. NCBI

3. What age does DFNA23 start?
   Often before speech or in early childhood; exact timing varies by family. PubMed+1

4. Will my hearing keep getting worse?
   Some reports describe stable loss; others note progression. The pattern can differ by the exact SIX1 variant. Regular testing helps track changes. Iris

5. Are there medicines that fix DFNA23?
   No. There are no FDA-approved drugs to reverse hereditary sensorineural hearing loss. Frontiers

6. What about gene therapy—is that available?
   Not yet. Gene therapy for hearing loss is in clinical trials (for example, OTOF-related deafness) and is not FDA-approved. NIDCD

7. Do cochlear implants help genetic hearing loss?
   Yes, many people with hereditary SNHL benefit. Outcomes are generally good when criteria are met and rehabilitation is strong. SpringerLink

8. Can diet or vitamins cure DFNA23?
   No. Some nutrients are linked to general ear health, but none cure genetic deafness. Use them only as supportive measures. PMC

9. Should children learn sign language if they get implants?
   Many experts recommend ensuring language access—spoken, signed, or both—so children don’t face language deprivation. The Guardian

10. Is DFNA23 rare?
    Yes. It’s one of many rare DFNA subtypes caused by different genes. MDPI

11. How is DFNA23 confirmed?
    Through genetic testing that finds a SIX1 variant consistent with the family history and hearing tests. NCBI

12. Can remote microphones help at school or work?
    Yes. They improve the speech signal over distance and noise. PMC

13. Are there risks to cochlear implant surgery?
    As with any surgery, yes (infection, dizziness, device failure). Your team will review risks vs benefits for your case; CIs are FDA-approved devices with defined indications. FDA Access Data

14. Will hearing aids make hearing “normal”?
    They improve audibility and clarity but do not restore normal hearing; success depends on fit, practice, and expectations. PMC

15. What can family members do?
    Consider genetic counseling and testing, use good communication strategies (face the listener, reduce background noise), and support early device fitting and therapy for children. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 03, 2025.